Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials

This publication has 9 references indexed in Scilit:

• Faricimab Treat-and-Extend for Diabetic Macular Edema
  Ophthalmology, 2023
• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
  The Lancet, 2022
• YOSEMITE and RHINE
  Ophthalmology Science, 2021
• Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
  Current Opinion in Ophthalmology, 2017
• Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)
  Ophthalmologica, 2017
• Anti–Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema
  JAMA Ophthalmology, 2016
• Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
  EMBO Molecular Medicine, 2016
• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
  Ophthalmology, 2016
• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
  New England Journal of Medicine, 2015